NDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
3/8 — Basic
PATADAY TWICE DAILY RELIEF (olopatadine hydrochloride) by Alcon is 1 receptor antagonist. First approved in 1996.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pataday Twice Daily Relief is an ophthalmic antihistamine solution containing olopatadine hydrochloride, a selective H1 receptor antagonist. It treats allergic conjunctivitis by blocking histamine-mediated allergic responses in the eye. The drug has been available since 1996 and is indicated for symptomatic relief of itching associated with allergic conjunctivitis.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team restructuring and transition to lifecycle management roles.
Mechanism of Action
1 receptor antagonist. The antihistaminic activity of olopatadine has been documented in isolated tissues, animal models, and humans.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects
Started Dec 2014
383 enrolled
Allergic Conjunctivitis
Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis
Started Apr 2011
Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis
Started Dec 2010
129 enrolled
Rhinitis, Allergic, SeasonalConjunctivitis, Allergic
Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients
Started Mar 2010
42 enrolled
Allergic Conjunctivitis
Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)
Started Jul 2008
50 enrolled
Allergic Conjunctivitis
Worked on PATADAY TWICE DAILY RELIEF at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.